155 related articles for article (PubMed ID: 38609583)
21. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients.
Gomes AS; Monteleone PA; Sayre JW; Finn RS; Sadeghi S; Tong MJ; Britten CD; Busuttil RW
AJR Am J Roentgenol; 2017 Oct; 209(4):722-732. PubMed ID: 28705059
[TBL] [Abstract][Full Text] [Related]
22. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
23. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, Safety, and Efficacy of Chemoembolization with Doxorubicin-Loaded Tightly Calibrated Small Microspheres in Patients with Hepatocellular Carcinoma.
Malagari K; Kiakidis T; Pomoni M; Moschouris H; Emmanouil E; Spiridopoulos T; Sotirchos V; Tandeles S; Koundouras D; Kelekis A; Filippiadis D; Charokopakis A; Bouma E; Chatziioannou A; Dourakis S; Koskinas J; Karampelas T; Tamvakopoulos K; Kelekis N; Kelekis D
Cardiovasc Intervent Radiol; 2016 Oct; 39(10):1379-91. PubMed ID: 27393274
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC
Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358
[TBL] [Abstract][Full Text] [Related]
26. Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 μm: Results from a Single-Centre Prospective Phase II Trial.
Malagari K; Moschouris H; Kiakidis T; Harward S; Kelekis A; Vrakas S; Koundouras D; Filipiadis D; Glantzounis G; Emmanouil E; Chatziioannou A; Vergadis V; Elefsiniotis I; Koskinas J; Dourakis S; Kelekis N
Cardiovasc Intervent Radiol; 2019 Nov; 42(11):1551-1562. PubMed ID: 31321482
[TBL] [Abstract][Full Text] [Related]
27. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
[TBL] [Abstract][Full Text] [Related]
28. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients.
Malagari K; Chatzimichael K; Alexopoulou E; Kelekis A; Hall B; Dourakis S; Delis S; Gouliamos A; Kelekis D
Cardiovasc Intervent Radiol; 2008; 31(2):269-80. PubMed ID: 17999110
[TBL] [Abstract][Full Text] [Related]
29. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma.
Liu YS; Ou MC; Tsai YS; Lin XZ; Wang CK; Tsai HM; Chuang MT
Korean J Radiol; 2015; 16(1):125-32. PubMed ID: 25598680
[TBL] [Abstract][Full Text] [Related]
30. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.
Lewis AL; Gonzalez MV; Lloyd AW; Hall B; Tang Y; Willis SL; Leppard SW; Wolfenden LC; Palmer RR; Stratford PW
J Vasc Interv Radiol; 2006 Feb; 17(2 Pt 1):335-42. PubMed ID: 16517780
[TBL] [Abstract][Full Text] [Related]
31. In vitro characterization of immune modulating drug-eluting immunobeads towards transarterial embolization in cancer.
Negussie AH; Mikhail AS; Owen JW; Hong N; Carlson CJ; Tang Y; Carrow KP; Mauda-Havakuk M; Lewis AL; Karanian JW; Pritchard WF; Wood BJ
Sci Rep; 2022 Dec; 12(1):21886. PubMed ID: 36535979
[TBL] [Abstract][Full Text] [Related]
32. Safety, Efficacy and Distribution of Doxorubicin Loaded Radiopaque Beads in Chemoembolization in Intermediate Stage Hepatocellular Carcinoma (HCC) with Correlation with Local Response.
Malagari Κ; Kiakidis T; Moschouris H; Deutsch M; Tanteles S; Pantou E; Panagiotou I; Koskinas J; Glantzounis GK; Alexopoulou A; Filippiadis D; Brountzos E; Kelekis N
Cardiovasc Intervent Radiol; 2023 Mar; 46(3):337-349. PubMed ID: 36653660
[TBL] [Abstract][Full Text] [Related]
33. A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials.
Wang H; Cao C; Wei X; Shen K; Shu Y; Wan X; Sun J; Ren X; Dong Y; Liu Y; Zhai B
J Cancer Res Ther; 2020; 16(2):243-249. PubMed ID: 32474508
[TBL] [Abstract][Full Text] [Related]
34. Sunitinib and PF-562,271 (FAK/Pyk2 inhibitor) effectively block growth and recovery of human hepatocellular carcinoma in a rat xenograft model.
Bagi CM; Christensen J; Cohen DP; Roberts WG; Wilkie D; Swanson T; Tuthill T; Andresen CJ
Cancer Biol Ther; 2009 May; 8(9):856-65. PubMed ID: 19458500
[TBL] [Abstract][Full Text] [Related]
35. Liver chemoembolization of hepatocellular carcinoma using TANDEM
Delicque J; Guiu B; Boulin M; Schwanz H; Piron L; Cassinotto C
Future Oncol; 2018 Nov; 14(26):2761-2772. PubMed ID: 29953255
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Chen J; Zhou C; Long Y; Yin X
Tumour Biol; 2015 Jan; 36(1):183-91. PubMed ID: 25217986
[TBL] [Abstract][Full Text] [Related]
37. Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.
Ait-Oudhia S; Mager DE; Pokuri V; Tomaszewski G; Groman A; Zagst P; Fetterly G; Iyer R
CPT Pharmacometrics Syst Pharmacol; 2016 Jun; 5(6):297-304. PubMed ID: 27300260
[TBL] [Abstract][Full Text] [Related]
38.
Chen Q; Shu L; Sun Y; Guo P; Wang D; Sha X
Cancer Biother Radiopharm; 2023 Oct; 38(8):512-520. PubMed ID: 33493417
[No Abstract] [Full Text] [Related]
39. The short-term safety and efficacy of TANDEM microspheres of various sizes and doxorubicin loading concentrations for hepatocellular carcinoma treatment.
Lin CY; Liu YS; Pan KT; Chen CB; Hung CF; Chou CT
Sci Rep; 2021 Jun; 11(1):12277. PubMed ID: 34112836
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
